Lexeo Therapeutics

Lexeo Therapeutics

Overview

Lexeo Therapeutics is a clinical-stage gene therapy company headquartered at 345 Park Avenue South, 6th Floor, New York, NY 10010, focused on developing adeno-associated virus (AAV)-based gene therapies for genetically defined cardiovascular and neurodegenerative diseases. The company's neurodegenerative pipeline targets Alzheimer's disease and other tauopathies using gene therapy approaches.[@lexeo]

Lexeo Therapeutics

Overview

Lexeo Therapeutics is a clinical-stage gene therapy company headquartered at 345 Park Avenue South, 6th Floor, New York, NY 10010, focused on developing adeno-associated virus (AAV)-based gene therapies for genetically defined cardiovascular and neurodegenerative diseases. The company's neurodegenerative pipeline targets Alzheimer's disease and other tauopathies using gene therapy approaches.[@lexeo]

Lexeo retains exclusive worldwide development and commercialization rights to all product candidates.

Company Information

| Attribute | Value |
|-----------|-------|
| Ticker | NASDAQ: LXEO |
| Founded | 2019 |
| Headquarters | New York, NY, USA |
| Focus | AAV gene therapy for genetic cardiovascular and CNS disorders |
| Status | Public company (IPO 2021) |

Funding History

| Year | Event | Amount |
|------|-------|--------|
| 2019 | Series A | ~$40 million |
| 2021 | IPO | ~$85 million |
| 2023 | Eli Lilly Partnership | Strategic |
| 2024 | Series C | $100+ million |

Clinical Pipeline

LX1001 (Lead CNS Program)

| Attribute | Value |
|-----------|-------|
| Target | APOE4 homozygous Alzheimer's disease |
| Gene Delivered | APOE2 (protective allele) |
| Delivery Route | Intrathecal (AAV) |
| Phase | Phase 1/2 (LEAD trial) |
| Designations | FDA Fast Track |

The flagship neurodegenerative program targets APOE4, the strongest genetic risk factor for late-onset Alzheimer's disease:[@apoe]

• Mechanism: Deliver a functional APOE2 gene (protective allele) to neurons
• Target: Patients homozygous for APOE4 (approximately 2-3% of AD cases)
• Delivery: Intrathecal (spinal) administration to achieve CNS delivery
• Status: Phase 1/2 ongoing (NCT03634007)
• Trial: LEAD trial (Lexeo Expression of APOE in Disease)

LX1021

| Attribute | Value |
|-----------|-------|
| Target | Alzheimer's Disease (Christchurch mutation) |
| Indication | APOE Christchurch carriers |
| Stage | Preclinical |

LX1020

| Attribute | Value |
|-----------|-------|
| Target | Alzheimer's Disease |
| Indication | APOE2+/E4- patients |
| Stage | Preclinical |

Cardiac Pipeline

LX2006 (Lead Cardiac Program)

| Attribute | Value |
|-----------|-------|
| Target | Friedreich Ataxia Cardiomyopathy |
| Gene | FXN (frataxin) |
| Phase | Phase 1/2 (SUNRISE-FA trial) |
| Designations | FDA Breakthrough Therapy, Regenerative Medicine Advanced Therapy, Orphan Drug, Rare Pediatric Disease |

LX2020

| Attribute | Value |
|-----------|-------|
| Target | Arrhythmogenic Cardiomyopathy |
| Gene | PKP2 |
| Stage | Preclinical |

LX2021

| Attribute | Value |
|-----------|-------|
| Target | Desmoplakin Cardiomyopathy |
| Gene | CX43 (Connexin 43) |
| Stage | Preclinical |

LX2022

| Attribute | Value |
|-----------|-------|
| Target | Hypertrophic Cardiomyopathy |
| Gene | TNNI3 (cardiac troponin I) |
| Stage | Preclinical |

Technology Platform

Lexeo's gene therapy platform includes:

• AAV Vectors: Adeno-associated viruses for safe, long-term gene delivery
• CNS Delivery: Specialized delivery methods for brain-targeted therapies
• Gene Replacement: Delivering functional copies of disease-causing genes
• Gene Silencing: Using RNA interference for dominant-negative mutations
• cGMP Manufacturing: Internal manufacturing capabilities for clinical-scale production

Clinical Trials

Ongoing Trials

| Trial | Phase | Sponsor |
|-------|-------|---------|
| SUNRISE-FA | Phase 1/2 | Lexeo Therapeutics |
| LEAD (LX1001) | Phase 1/2 | Lexeo |
| Investigator-initiated Phase 1A | Phase 1 | Weill Cornell Medicine |

Supporting Studies

• CLARITY-FA: Natural history study for Friedreich Ataxia
• Weill Cornell Medicine investigator-initiated trial

APOE4 Biology

APOE4 carriers have significantly increased Alzheimer's risk:

• Homozygous APOE4: ~12x increased risk vs. APOE3
• Associated with increased amyloid deposition
• Impaired amyloid clearance
• Enhanced tau pathology

Key People

• R. Nolan Townsend (CEO)
• Dr. James M. (Co-founder and Chief Scientific Officer)
• Dr. Steven G. (Chief Medical Officer)
• Dr. Ronald G. (Co-founder and Chairman)

Partnerships

• Weill Cornell Medicine: Investigator-initiated trial collaboration
• Eli Lilly: Strategic partnership (2023)

Manufacturing

Lexeo operates internal cGMP manufacturing capabilities for AAV vector production, enabling clinical-scale manufacturing for their pipeline.

Cross-References

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• APOE Gene
• [Tau](/proteins/tau) Pathology](/mechanisms/tau-pathology)
• [Amyloid](/mechanisms/amyloid-aggregation) Pathology
• [Gene Therapy](/therapeutics/gene-therapy-neurodegeneration) Friedreich Ataxia
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/genes/ar)
• [APOE4](/diseases/apoe4)

External Links

• [Lexeo Therapeutics Website](https://www.lexeotx.com)
• [ClinicalTrials.gov - LX1001](https://clinicaltrials.gov/study/NCT03634007)

References

See Also

• [Neuroinflammation and Microglia Pathway in Alzheimer's Disease](/wiki/mechanisms-ad-neuroinflammation-microglia-pathway) — inhibits